The current role of post-mastectomy radiotherapy as an adjuvant
treatment in stage II breast cancer has been challenged. Although
adjuvant radiation was once an established therapy in the management
of breast cancer, the routine use of systemic therapy in patients
at significant risk for distant (and local) dissemination has
caused some to question the need for locoregional radiotherapy.
Several issues must be considered when weighing the relative merits
of adjuvant locoregional radiotherapy:
- Can systemic therapy improve locoregional control comparable
to that achieved with radiotherapy, such that the addition of
post-mastectomy radiotherapy offers no further benefit?
- ·Are there subgroups of women at high risk for locoregional
failure who would particularly benefit from the use of post-mastectomy
- ·If post-mastectomy radiotherapy improves locoregional
control in the presence of chemotherapy, could this have an impact
on overall survival?
To begin to understand the importance of post-mastectomy radiotherapy
in the current management of breast cancer, it is necessary to
first look at the role this modality has played prior to the use
of systemic treatment. Also, when formulating current recommendations
for the use of post-mastectomy radiotherapy, it is important to
extrapolate the lessons learned from the early trials.
Analyses of locoregional failure have shown the chest wall to
be the most common site of failur [1-3]. Halverson et al reported
the chest wall to be the site of isolated locoregional recurrence
in 60% of patients with a locoregional failure, with an additional
10% of patients having the chest wall as a component of failure,
so that the chest wall was involved in 70% of the locoregional
The mastectomy scar is at greatest risk for recurrence . Donegan
et al reported the scar or grafted area to be the most frequent
site of chest wall involvement, accounting for 42% of such recurrences
. In most series, the supraclavicular/infraclavicular nodes
are the second most common site of locoregional failure, with
involvement as a single site in 10% to 20% patients.
Clinical recurrences occur less frequently in the internal mammary
nodes or in the axilla. From 5% to 10% of patients present with
an isolated failure at each site in an adequately dissected axilla
Predictors of Locoregional Failure Following Mastectomy Alone
Additional analyses have identified various factors that are predictive
of increased locoregional failure.
Positive Axillary Nodes--The finding of positive axillary
nodes has been shown consistently to be the major predictor of
chest wall failure [4,6,7]. Haagensen reported in one of the earliest
series, factors that predicted a local recurrence following mastectomy
. Of 935 patients with either stage I or II disease treated
with radical mastectomy and followed for at least 10 years, axillary
node involvement was closely related to the risk of chest wall
recurrence, with recurrence rates up to 42% in patients with four
or more nodes positive.
Donegan et al performed a similar analysis of locally recurrent
breast cancer following radical mastectomy . Among the 704
women studied, only 6.5% of patients with histologically uninvolved
axillary nodes had a local recurrence at 5 years, as compared
with 26% of women with pathologically involved nodes. The percentage
of local recurrence was directly correlated with the absolute
number of positive nodes: Involvement of 1 to 3 nodes was associated
with a 10% to 15% recurrence rate at 5 years; this rate increased
to 25% to 38% with 4 to 7 positive nodes and to 43% or higher
with 8 or more positive nodes.
In a trial from Stockholm, in which women were randomized to post-mastectomy
radiotherapy, histologic lymph node status was an independent
predictor of local recurrence. The relative risk for local failure
was three times greater among women with positive nodes than among
those with negative nodes .
Other factors have also been associated with increased
locoregional failure following mastectomy in the absence of systemic
therapy. The size of the primary lesion has been correlated with
local recurrence in some series [4,8-10]. Donegan and colleagues
found a direct association between tumor diameter and local recurrence,
with 0% of patients with tumors less than 1.0 cm having a local
failure, increasing to 16% for tumors 3.0 to 3.9 cm, 27% for lesions
5.0 to 5.9 cm, and greater than 30% for tumors exceeding 6.0 cm
. This study did not correct for the presence of positive axillary
nodes, however, in determining this association.
In series reported by Rosenman et al  and Valagussa et al ,
tumor size was strongly correlated with locoregional recurrence
in node-positive patients. Pathologic factors found in the Cancer
Research Campaign Trial to independently predict for increased
locoregional recurrence included the size of the primary lesion
Distance of the tumor to the pectoralis fascia may also affect
local failure. In one series examining local recurrence as a function
of the distance to the deep resection margin, seven of eight patients
with local recurrence had a margin of 0.5 cm or less .
Other factors that may also have an impact on chest wall recurrence
include lymphatic invasion and tumor grade [10,12].
Quality of life can be severely compromised by a locoregional
failure following mastectomy. Subsequent rates of locoregional
control with radiotherapy following a recurrence have been disappointing.
Reported control rates have ranged between 25% and 76%, depending
on tumor bulk and resectability, with an average control rate
of 50% [1-3,5]. Thus, even with optimal radiotherapy, 50% of patients
experiencing a locoregional failure will die with uncontrolled
locoregional disease. This argues strongly in favor of the delivery
of prophylactic radiotherapy following mastectomy for maximal
local control. In recent series in which radiotherapy has been
delivered to high-risk patients in conjunction with chemotherapy,
isolated locoregional recurrences have been reduced to 5% to 10%
It has also been suggested that increased locoregional control
influences survival. In every surgical series of stage I or II
breast cancer to date, locoregional therapy as sole therapy has
been curative in a majority of node- negative patients and a minority
of node-positive women [4,6,9]. Therefore, a finite percentage
of early-stage breast cancers are confined locoregionally and
are cured by definitive locoregional treatment. Conversely, a
minority of node-negative women and a majority of node-positive
women whose disease is locally controlled develop sites of distant
Sequential National Surgical Adjuvant Breast Project (NSABP) studies
comparing locoregional therapies have shown little correlation
between local control and overall survival [14,15]. Based on these
results, Fisher et al hypothesized that breast cancer is a systemic
disease at presentation, and that local control has little to
no impact on survival. An alternative hypothesis proposed by Hellman
suggests that breast cancer is a heterogeneous disease in which
subsets of women present with systemic disease, whereas others
have disease restricted to locoregional sites at diagnosis .
In the latter group, locoregional control would surely influence
outcome. Therefore, for reasons including both quality of life
and, potentially, overall survival, the maintenance of locoregional
control is an important goal.
1. Halverson K, Perez C, Kuske R, et al: Isolated local-regional
recurrence of breast cancer following mastectomy: Radiotherapeutic
management. Int J Radiat Oncol Biol Phys 19:851-858, 1990.
2. Schwaibold F, Fowble BL, Solin LJ, et al: The results of radiation
therapy for isolated local regional recurrence after mastectomy.
Int J Radiat Oncol Biol Phys 21:299-310, 1991.
3. Toonkel L, Fix I, Jacobson L, et al: The significance of local-regional
recurrence of carcinoma of the breast. Int J Radiat Oncol Biol
Phys 9:33-39, 1983.
4. Donegan WL, Perez-Mesa CM, Watson FR: A biostatistical study
of locally recurrent breast carcinoma. Surg Gynecol Obstet
5. Bedwinek J: Natural history and management of isolated local-regional
recurrence following mastectomy. Semin Radiat Oncol 4:260-269,
6. Haagensen CD, Bodian C: A personal experience with Halsted's
radical mastectomy. Ann Surg 199:143-150, 1984.
7. Arriagada R, Rutqvist LE, Mattson A, et al: Adequate locoregional
treatment for early breast cancer may prevent secondary dissemination.
J Clin Oncol 13:2869-2878, 1995.
8. Rosenman J, Bernard S, Kober C, et al: Local recurrences in
patients with breast cancer at the North Carolina Memorial Hospital
(1970-1982). Cancer 57:1421-1425, 1986.
9. Valagussa P, Bonadonna G, Veronesi U: Patterns of relapse and
survival following radical mastectomy: Analysis of 716 consecutive
patients. Cancer 41:1170-1178, 1978.
10. Houghton J, Baum M, Haybittle JL: Role of radiotherapy following
total mastectomy in patients with early breast cancer: The Closed
Trials Working Party of the CRC Breast Cancer Trials Group.
World J Surg 18:117-122, 1994.
11. Mentzer SJ, Osteen RT, Wison RE: Local recurrence and the
deep resection margin in carcinoma of the breast. Surg Gynecol
Obstet 163:513-517, 1986.
12. O'Rourke S, Galea MH, Morgan D, et al: Local recurrence after
simple mastectomy. Br J Surg 81:386-389, 1994.
13. Fowble B, Glick J, Goodman R: Radiotherapy for the prevention
of local-regional recurrence in high rish patients post mastectomy
receiving adjuvant chemotherapy. Int J Radiat Oncol Biol Phys
14. Fisher B, Redmond C, Fisher ER, et al: Ten-year results of
a randomized clinical trial comparing radical mastectomy and total
mastectomy with or without radiation. N Engl J Med 312:674-681,
15. Fisher B, Anderson S, Redmond C, et al: Reanalysis and results
after 12 years of follow-up in a randomized clinical trial comparing
total mastectomy with lumpectomy with or without irradiation in
the treatment of breast cancer. N Engl J Med 333:1456-1461,
16. Hellman S: Natural history of small breast cancers (Karnofsky
memorial lecture). J Clin Oncol 12:2229-2234, 1994.
17. Jones JM, Ribeiro GG: Mortality patterns over 34 years of
breast cancer patients in a clinical trial of post-operative radiotherapy.
Clin Radiol 40:204-208, 1989.
18. Host H, Brennhovd IO, Loeb M, et al: Postoperative radiotherapy
in breast cancer--long-term results from the Oslo study. Int J
Radiat Oncol Biol Phys 12:727-732, 1986.
19. Fisher B, Slack NH, Cavanaugh PJ, et al: Postoperative radiotherapy
in the treatment of breast cancer: Results of the NSABP clinical
trial. Ann Surg 172:711-732, 1970.
20. Rutqvist LE, Pettersson D, Johansson H: Adjuvant radiation
therapy versus surgery alone in operable breast cancer: Long-term
follow-up of a randomized clinical trial. Radiother Oncol
21. Lythgoe JP, Palmer MK: Manchester regional breast study--5
and 10 year results. Br J Surg 69:693-696, 1982.
22. Turnbull AR, Turner DT, Chant AD, et al: Treatment of early
breast cancer. Lancet 2:7-9, 1978.
23. Forrest AP, Stewart HJ, Roberts MM, et al: Simple mastectomy
and axillary node sampling (pectoral node biopsy) in the management
of primary breast cancer. Ann Surg 196:371-378, 1982.
24. Fletcher GH: Clinical dose-response curves of human malignant
epithelial tumours. Br J Radiol 46:1-12, 1973.
25. Cuzick J, Stewart H, Peto R, et al: Overview of randomized
trials of postoperative adjuvant radiotherapy in breast cancer.
Cancer Treat Rep 71:15-29, 1987.
26. Cuzick J, Stewart H Rutqvist, L, et al: Cause-specific mortality
in long-term survivors of breast cancer who participated in trials
of radiotherapy. J Clin Oncol 12:447-453, 1973.
27. Early Breast Cancer Trialists' Collaborative Group: Effects
of radiotherapy and surgery in early breast cancer. N Engl
J Med 333:1444-1455, 1995.
28. Richards MA, O'Reilly, SM, Howell A, et al: Adjuvant cyclophosphamide,
methotrexate, and fluorouracil in patients with axillary node-positive
breast cancer: An update of the Guy's/Manchester trial. J Clin
Oncol 8:2032-2039, 1990.
29. Fisher B, Fisher ER, Redmond C: Ten-year results from the
National Surgical Adjuvant Breast and Bowel Project (NSABP) clinical
trial evaluating the use of L-phenylalanine mustard (L-PAM) in
the management of primary breast cancer. J Clin Oncol l4:929-941,
30. Morrison JM, Howell A, Kelly KA, et al: West Midlands Oncology
Association trials of adjuvant chemotherapy in operable breast
cancer: Results after a median follow-up of 7 years. Br J Cancer
31. Bonadonna G, Valagussa P, Molitern A, et al: Adjuvant cyclophosphamide,
methotrexate, and fluorouracil in node-positive breast cancer:
The results of 20 years of follow-up. N Engl J Med 332:901-906,
32. Marks LB, Halperin EC, Prosnitz LR, et al: Post-mastectomy
radiotherapy following adjuvant chemotherapy and autologous bone
marrow transplantation for breast cancer patients with greater
than or equal to 10 positive axillary lymph nodes: Cancer and
Leukemia Group B. Int J Radiat Oncol Biol Phys 23:1021-1026,
33. Peters W, Ross M, Vredenburgh J, et al: High-dose chemotherapy
and autologous bone marrow support as consolidation after standard-dose
adjuvant therapy for high-risk primary breast cancer. J Clin
Oncol 11:1132-1132, 1993.
34. Castiglione-Gertsch M, Johnsen C, Goldhirsch A, et al: The
International (Ludwig) Breast Cancer Study Group trials I-IV:
15 years follow-up. Ann Oncol 5:717-724, 1994.
35. Rutqvist LE, Cedermark B, Glas V, et al: Randomized trial
of adjuvant tamoxifen combined with postoperative radiation therapy
or adjuvant chemotherapy in postmenopausal breast cancer. Cancer
36. Stefanik D, Goldberg R, Byrne P, et al: Local-regional failure
in patients treated with adjuvant chemotherapy for breast cancer.
J Clin Oncol 3:660-665, 1985.
37. Fowble B, Gray R, Gilchrist K, et al: Identification of a
subgroup of patients with breast cancer and histologically positive
axillary nodes receiving adjuvant chemotherapy who may benefit
from postoperative radiotherapy. Cancer 6:1107-1117, 1988.
38. Pisansky TM, Ingle JN, Schaid DJ, et al: Patterns of tumor
relapse following mastectomy and adjuvant systemic therapy in
patients with axillary lymph node-positive breast cancer: Impact
of clinical, histopathologic, and flow cytometric factors. Cancer
39. Sykes HF, Sim DA, Wong CJ, et al: Local-regional recurrence
in breast cancer after mastectomy and adriamycin-based adjuvant
chemotherapy: evaluation of the role of postoperative radiotherapy.
Int J Radiat Oncol Biol Phys 16:641-647, 1989.
40. Martinez A, Ahmann D, O'Fallow J, et al: An interim analysis
of the randomized surgical adjuvant trial for patients with unfavorable
breast cancer. Int J Radiat Oncol Biol Phys 10(suppl 2):106,
41. McArdle CS, Crawford D, Dykes EH, et al: Adjuvant radiotherapy
and chemotherapy in breast cancer. Br J Surg 73:264-266,
42. Muss H, Cooper R, Brockschmidt J, et al: A randomized trial
of adjuvant chemotherapy with and without radiation therapy for
stage II breast cancer: 11 year follow-up of Piedmont Oncology
Association protocol 74176. Breast Cancer Res Treat 14:185,
43. Griem KL, Henderson IC, Gelman R, et al: The 5-year results
of a randomized trial of adjuvant radiation therapy after chemotherapy
in breast cancer patients treated with mastectomy. J Clin Oncol
44. Blomqvist C, Tiusanen K, Elomaa I, et al: The combination
of radiotherapy, adjuvant chemotherapy (cyclophosphamide-doxorubicin-ftorafur)
and tamoxifen in stage II breast cancer: Long-term follow-up results
of a randomised trial. Br J Cancer 66:1171-1176, 1992.
45. Velez-Garcia E, Carpenter JT, Moore M, et al: Postsurgical
adjuvant chemotherapy with or without radiotherapy in women with
breast cancer and positive axillary nodes: A Southeastern Cancer
Study Group trial. Eur J Cancer 11:1833-1837, 1992.
46. Buzdar AU, Blumenshein GR, Smith TL, et al: Adjuvant chemotherapy
with fluorouracil, doxorubicin, and cyclophosphamide, with or
without irradiation in operable breast cancer: A prospective randomized
trial. Cancer 53:384-389, 1984.
47. Ragaz J, Jackson SM, Le N, et al: Can adjuvant locoregional
radiotherapy reduce systematic recurrence in stage I-II breast
cancer patients? Recurrence analysis of the British Columbia randomized
trial (abstract). Proc Am Soc Clin Oncol 15: A150, 1996.
48. Overgaard M: The role of postmastectomy radiotherapy in high-risk
breast cancer patients receiving adjuvant systemic therapy. 5th
International Meeting of Progress in Radio-Oncology ICRO/OGRO,
p 41-45. Bologna (Italy), Monduzzi Editore, 1995.
49. Overgaard M, Christensen JJ, Johansen H, et al: Evaluation
of radiotherapy in high-risk breast cancer patients: report from
the Danish Breast Cancer Cooperative Group (DBCG 82) Trial. Int
J Radiat Oncol Biol Phys 19:1121-1124, 1990.
50. Lara Jimenez P, Garcia Puche J, Pedraza V: Adjuvant combined
modality treatment in high risk breast cancer patients: 10 year
results. 5th EORTC Breast Cancer Working Conference, Leuven, Belgium,
51. Pierce LJ, Lichter AS, Archer P: Indications, integration,
and technical aspects of local-regional irradiation in the management
of advanced breast cancer. Semin Radiat Oncol 4:242-253,
52. Danoff BF, Galvin JM, Cheg E, et al: The clinical application
of CT scanning in the treatment of primary breast cancer, in Current
Controversies in Breast Cancer, pp 391-397. Austin, Texas,
University of Texas Press, 1984.
53. Shapiro CL, Recht A: Late effects of adjuvant therapy for
breast cancer. J Natl Cancer Inst Monogr 16:101-112, 1994.
54. Harrigan P, Otis D, Recht A, et al: The effect of adjuvant
radiation therapy on cardiac events in breast cancer patients
treated with doxorubicin. Proc Am Soc Clin Oncol 14:102,
55. Hellman S, Weichselbaum R: Radiation oncology and the new
biology. Cancer J Sci Am 1:174-179, 1995.